80 research outputs found
Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia
INTRODUCTION: Hyperprolactinaemia, a common adverse effect of antipsychotic drugs, is primarily linked to blockade of dopamine D2 receptors in the pituitary gland. Certain antipsychotic drugs, such as, for example risperidone and paliperidone, are more likely to induce hyperprolactinaemia compared to others. This effect is probably caused by a relatively high blood/brain concentration ratio, a consequence of being a substrate of P-glycoprotein. Genetic variants of P-glycoprotein with changed functional activity might influence the potential of risperidone and paliperidone to cause hyperprolactinaemia as the altered blood/brain concentration ratio would lead to a reduced therapeutic drug level within essential brain areas making dose adaptations necessary. This increases exposure of dopamine D2 receptors within the pituitary gland. AIMS: To investigate possible associations between MDR1/ABCB1 gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia in Russian patients with schizophrenia and to determine possible differences between risperidone/paliperidone and other antipsychotics. METHODS: In total, 446 patients with schizophrenia were included from 3 psychiatric hospitals in Siberia. Blood samples were obtained in a cross-sectional study design for DNA extraction and prolactin measurement. Associations between hyperprolactinaemia and 8 MDR1/ABCB1 gene-polymorphisms were assessed using logistic regression analysis accounting for covariates. The analysis was repeated in a patient subgroup using risperidone or paliperidone. RESULTS: We did not observe an association between any of the 8 single nucleotide polymorphisms and the prevalence of antipsychotic-induced hyperprolactinaemia in the total patient population. However, in the risperidone/paliperidone subgroup, the single nucleotide polymorphism rs2032582 (G2677T) was found to be negatively associated with risperidone/paliperidone-induced hyperprolactinaemia. CONCLUSION: This study revealed a significant association between the ABCB1 gene polymorphism rs2032582 (G2677T) and risperidone/paliperidone-induced hyperprolactinaemia
Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia
ΠΡΠ΅Π½ΠΊΠ° Π²Π»ΠΈΡΠ½ΠΈΡ ΡΠΎΠ»Π΅ΠΉ Π»ΠΈΡΠΈΡ Π½Π° ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ ΠΊΡΠΎΠ²ΠΈ Π² ΠΎΠΏΡΡΠ°Ρ in vitro
Aim. To study the effects of lithium salts on production of cytokines by immunocompetent cells in the whole-blood culture of patients with alcohol dependence and affective disorders.Materials and methods. The study materials were blood samples from 25 patients with alcohol dependence (AD) and 12 patients with bipolar disorder (BD). Blood diluted 1:1 with complete RPMI-1640 medium (Gibco, UK) was added to the wells of the culture plate, then new lithium salts (succinate, fumarate, pyruvate, ascorbate) and a reference salt β lithium carbonate at a final concentration of 1.2 mmol / l per lithium ion β were added. In parallel, control samples without lithium salts were tested; the samples were incubated for a day. The concentration of cytokines (interferon (IFN) Ξ³, interleukin (IL)-1Ξ², IL-2, IL-4, IL-6, IL-8, IL-10, IL-17A, tumor necrosis factor (TNF) Ξ±) was determined in the culture supernatants on the MAGPIX multiplex analyzer (Luminex, USA) (Center for Collective Use βMedical Genomicsβ, Tomsk NRMC) using the Human Cytokine / Chemokine Magnetic Bead Panel (Merck, Germany).Results. All lithium salts had a unidirectional effect on the production of cytokines by immunocompetent cells (ICC), except for lithium ascorbate and IL-8. The concentrations of cytokines in the supernatants of loaded and control samples (spontaneous production) were comparable, which indicates an absence of stimulating or suppressing effects of salts on the functional activity of ICC under the experimental conditions. The effect of lithium ascorbate as an IL-8 inducer was detected: the production of IL-8 induced by lithium ascorbate was 2.3β2.5 times higher than its spontaneous production.Conclusion. The obtained results, as well as the previously revealed antioxidant and cytoprotective properties of new lithium salts, confirmed that they are promising for development of pharmacological agents with combined action.Π¦Π΅Π»Ρ β ΠΈΠ·ΡΡΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠΎΠ»Π΅ΠΉ Π»ΠΈΡΠΈΡ Π½Π° ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² ΠΈΠΌΠΌΡΠ½ΠΎΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½ΡΠΌΠΈ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ Π² ΠΊΡΠ»ΡΡΡΡΠ΅ ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡΡ ΠΈ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌΠΈ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π°ΠΌΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠΌ Π΄Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΡΠ»ΡΠΆΠΈΠ»ΠΈ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΊΡΠΎΠ²ΠΈ 25 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡΡ ΠΈ 12 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π±ΠΈΠΏΠΎΠ»ΡΡΠ½ΡΠΌ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²ΠΎΠΌ. Π Π»ΡΠ½ΠΊΠΈ ΠΊΡΠ»ΡΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΠ»Π°Π½ΡΠ΅ΡΠ° Π²Π½ΠΎΡΠΈΠ»ΠΈ ΠΊΡΠΎΠ²Ρ, ΡΠ°Π·Π²Π΅Π΄Π΅Π½Π½ΡΡ 1 : 1 ΠΏΠΎΠ»Π½ΠΎΠΉ ΡΡΠ΅Π΄ΠΎΠΉ RPMI-1640 (Gibco, ΠΠ΅Π»ΠΈΠΊΠΎΠ±ΡΠΈΡΠ°Π½ΠΈΡ), Π΄ΠΎΠ±Π°Π²Π»ΡΠ»ΠΈ Π½ΠΎΠ²ΡΠ΅ ΡΠΎΠ»ΠΈ Π»ΠΈΡΠΈΡ (ΡΡΠΊΡΠΈΠ½Π°Ρ, ΡΡΠΌΠ°ΡΠ°Ρ, ΠΏΠΈΡΡΠ²Π°Ρ, Π°ΡΠΊΠΎΡΠ±Π°Ρ) ΠΈ ΡΠΎΠ»Ρ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ β ΠΊΠ°ΡΠ±ΠΎΠ½Π°Ρ Π»ΠΈΡΠΈΡ Π² ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ 1,2 ΠΌΠΌΠΎΠ»Ρ/Π» Π² ΡΠ°ΡΡΠ΅ΡΠ΅ Π½Π° ΠΈΠΎΠ½ Π»ΠΈΡΠΈΡ, ΠΏΠ°ΡΠ°Π»Π»Π΅Π»ΡΠ½ΠΎ ΡΡΠ°Π²ΠΈΠ»ΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΠ΅ ΠΏΡΠΎΠ±Ρ Π±Π΅Π· ΡΠΎΠ»Π΅ΠΉ Π»ΠΈΡΠΈΡ; ΠΏΡΠΎΠ±Ρ ΠΈΠ½ΠΊΡΠ±ΠΈΡΠΎΠ²Π°Π»ΠΈ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΡΡΠΎΠΊ. Π ΡΡΠΏΠ΅ΡΠ½Π°ΡΠ°Π½ΡΠ°Ρ
ΡΡΡΠΎΡΠ½ΠΎΠΉ ΠΊΡΠ»ΡΡΡΡΡ Π½Π° ΠΌΡΠ»ΡΡΠΈΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΌ Π°Π½Π°Π»ΠΈΠ·Π°ΡΠΎΡΠ΅ MAGPIX (Luminex, Π‘Π¨Π) (Π¦ΠΠ Β«ΠΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ°Ρ Π³Π΅Π½ΠΎΠΌΠΈΠΊΠ°Β», Π’ΠΎΠΌΡΠΊΠΈΠΉ ΠΠΠΠ¦) ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² (ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π° Ξ³, ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π° (ΠΠ) 1Ξ², ΠΠ-2, ΠΠ-4, ΠΠ-6, ΠΠ-8, ΠΠ-10, ΠΠ-17Π, ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Ξ±) Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π½Π°Π±ΠΎΡΠΎΠ² ΡΠ΅Π°Π³Π΅Π½ΡΠΎΠ² Human Cytokine/Chemokine Magnetic Bead Panel (Merck, ΠΠ΅ΡΠΌΠ°Π½ΠΈΡ).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠ΅ ΡΠΎΠ»ΠΈ Π»ΠΈΡΠΈΡ ΠΎΠΊΠ°Π·ΡΠ²Π°Π»ΠΈ ΠΎΠ΄Π½ΠΎΠ½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΠΎΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π½Π° ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ ΡΠΏΠ΅ΠΊΡΡΠ° ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² ΠΈΠΌΠΌΡΠ½ΠΎΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½ΡΠΌΠΈ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ (ΠΠΠ) Π·Π° ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ΠΌ Π°ΡΠΊΠΎΡΠ±Π°ΡΠ° Π»ΠΈΡΠΈΡ ΠΈ ΠΠ-8. ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² Π² ΡΡΠΏΠ΅ΡΠ½Π°ΡΠ°Π½ΡΠ°Ρ
Π½Π°Π³ΡΡΠ·ΠΎΡΠ½ΡΡ
ΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΠ± (ΡΠΏΠΎΠ½ΡΠ°Π½Π½Π°Ρ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ) Π±ΡΠ»ΠΈ ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΡ, ΡΡΠΎ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎΠ± ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ ΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡΠ΅Π³ΠΎ ΠΈΠ»ΠΈ ΡΡΠΏΡΠ΅ΡΡΠΈΡΡΡΡΠ΅Π³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΡΠΎΠ»Π΅ΠΉ Π½Π° ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΠΠ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°. ΠΠ±Π½Π°ΡΡΠΆΠ΅Π½ ΡΡΡΠ΅ΠΊΡ Π°ΡΠΊΠΎΡΠ±Π°ΡΠ° Π»ΠΈΡΠΈΡ ΠΊΠ°ΠΊ ΠΈΠ½Π΄ΡΠΊΡΠΎΡΠ° ΠΠ-8: ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ Π°ΡΠΊΠΎΡΠ±Π°ΡΠΎΠΌ Π»ΠΈΡΠΈΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ ΠΠ-8 Π² 2,3β2,5 ΡΠ°Π·Π° ΠΏΡΠ΅Π²ΡΡΠ°Π»Π° Π΅Π³ΠΎ ΡΠΏΠΎΠ½ΡΠ°Π½Π½ΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ, Π° ΡΠ°ΠΊΠΆΠ΅ Π²ΡΡΠ²Π»Π΅Π½Π½ΡΠ΅ ΡΠ°Π½Π΅Π΅ Π°Π½ΡΠΈΠΎΠΊΡΠΈΠ΄Π°Π½ΡΠ½ΡΠ΅, ΡΠΈΡΠΎΠΏΡΠΎΡΠ΅ΠΊΡΠΎΡΠ½ΡΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π½ΠΎΠ²ΡΡ
ΡΠΎΠ»Π΅ΠΉ Π»ΠΈΡΠΈΡ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°ΡΡ ΠΈΡ
ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π΄Π»Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ΅Π΄ΡΡΠ² ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΠΈ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ² ΠΈ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ
The aim was to study the clinical-psychopathological, clinical-follow-up, clinical-dynamic features of mood disorders (MD) and alcohol use disorder (AUD) with their comorbidity combinations.Materials and methods. The study included 88 people with AUD and MD: 33 women (37.5%) and 55 (62.5%) men. The first group was 31 patients (35,0%) with AUD without comorbid affective symptoms, the second was 29 patients (33.0%) with MD without alcohol dependence, and the third was 28 patients (32.0%) with comorbid AUD and MD. There were no statistically significant differences between the groups by age and sex composition, by the level of statistical significance of differences (p = 0.115 β by sex, Γ° = 0.248 β by age). The study used clinical, psychopathological, clinical and follow-up, clinical, dynamic and statistical methods. Statistical processing was performed using Pearsonβs Ο2, Mann β Whitney U-test for comparing independent samples and Spearmanβs correlation analysis (r).Results. Patients of the second and third groups were diagnosed with dysthymia more rarely in statistically significant values by the level of statistical significance of differences (10.4% and 32.1% respectively, p = 0.023) and this testifies to MD taking chronic course in patients with AUD. The average duration of bout of heavy-drinking in the first group was longer than in the third group β 7 (4; 17) and 5,5 (3.5; 9.5) days accordingly (p = 0.043). Duration of the disease in the first and third groups was 10 (6; 18.5) and 14 (10; 19.75) years, respectively (p = 0.036). It confirms the negative impact of comorbidity on the clinicaldynamic features in the case of co-existing of AUD and MD.Conclusion. The coexistence of alcohol dependence and affective pathology enhances the suicidal risk of certain diseases. A tendency to the early appearance of symptoms of AUD and their rapid dynamics, a shorter duration of light intervals of MD and AUC, a relatively low tolerance to alcohol and pronounced depressogenic effect of alcohol in the case of comorbidity were found.Β Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΏΡΠΈΡ
ΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
, ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΊΠ°ΡΠ°ΠΌΠ½Π΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
, ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ² (ΠΠ ) ΠΈ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ (ΠΠ) ΠΏΡΠΈΠΈΡ
ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΡΡ
ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΡΡ
.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 88 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ Ρ ΠΠ ΠΈ ΠΠ β 33 ΠΆΠ΅Π½ΡΠΈΠ½Ρ (37,5%) ΠΈ 55 (62,5%)ΠΌΡΠΆΡΠΈΠ½. ΠΠ΅ΡΠ²Π°Ρ Π³ΡΡΠΏΠΏΠ° β 31 ΠΏΠ°ΡΠΈΠ΅Π½Ρ (35,0%) Ρ ΠΠ Π±Π΅Π· ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΠΉ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΠΊΠΈ,Π²ΡΠΎΡΠ°Ρ β 29 Π±ΠΎΠ»ΡΠ½ΡΡ
(33,0%) Ρ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²ΠΎΠΌ Π½Π°ΡΡΡΠΎΠ΅Π½ΠΈΡ Π±Π΅Π· Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π°Π»ΠΊΠΎΠ³ΠΎΠ»Ρ, ΡΡΠ΅ΡΡΡ β 28ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (32,0%) Ρ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΠ ΠΈ ΠΠ . ΠΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ ΠΏΠΎ ΠΏΠΎΠ»ΠΎΠ²ΠΎΠ·ΡΠ°ΡΡΠ½ΠΎΠΌΡ ΡΠΎΡΡΠ°Π²ΡΠΏΠΎ ΡΡΠΎΠ²Π½Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π½Π΅ Π²ΡΡΠ²Π»Π΅Π½ΠΎ (p = 0,115 β ΠΏΠΎ ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΌΡ ΡΠΎΡΡΠ°Π²Ρ, Ρ= 0,248 β ΠΏΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΠΎΠΌΡ ΡΠΎΡΡΠ°Π²Ρ). Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΏΡΠΈΡ
ΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ,ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΊΠ°ΡΠ°ΠΌΠ½Π΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ, ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΡΡ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Ο2 ΠΠΈΡΡΠΎΠ½Π°, U-ΠΊΡΠΈΡΠ΅ΡΠΈΡ ΠΠ°Π½Π½Π° β Π£ΠΈΡΠ½ΠΈ Π΄Π»Ρ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΡ
Π²ΡΠ±ΠΎΡΠΎΠΊ ΠΈ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π‘ΠΏΠΈΡΠΌΠ΅Π½Π° (r).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π²ΡΠΎΡΠΎΠΉ ΠΈ ΡΡΠ΅ΡΡΠ΅ΠΉ Π³ΡΡΠΏΠΏ ΠΏΠΎ ΡΡΠΎΠ²Π½Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΠΉΡΠ΅ΠΆΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π»Π°ΡΡ Π΄ΠΈΡΡΠΈΠΌΠΈΡ (10,4 ΠΈ 32,1% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, p = 0,023), ΡΡΠΎ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎΡ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Π² Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ
ΠΠ. Π‘ΡΠ΅Π΄Π½ΡΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΏΡΠ΅Π²Π΄ΠΎΠ·Π°ΠΏΠΎΠ΅Π² Π² ΠΏΠ΅ΡΠ²ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±ΡΠ»Π° Π²ΡΡΠ΅ β 7 (4; 17) ΡΡΡ, ΡΠ΅ΠΌ Π²ΡΡΠ΅ΡΡΠ΅ΠΉ Π³ΡΡΠΏΠΏΠ΅ β 5,5 (3,5; 9,5) (p = 0,043). ΠΠ°Π²Π½ΠΎΡΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π² ΠΏΠ΅ΡΠ²ΠΎΠΉ ΠΈ ΡΡΠ΅ΡΡΠ΅ΠΉ Π³ΡΡΠΏΠΏΠ°Ρ
ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 10 (6; 18,5) ΠΈ 14 (10; 19,75) Π»Π΅Ρ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ (p = 0,036), ΡΡΠΎ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°Π΅Ρ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΠΈ Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΡΠΈ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ ΠΠ ΠΈ ΠΠ .ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘ΠΎΡΡΡΠ΅ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΠ ΠΈ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΡΠΈΠ»ΠΈΠ²Π°Π΅Ρ ΡΡΠΈΡΠΈΠ΄Π°Π»ΡΠ½ΡΠΉ ΡΠΈΡΠΊ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ; Π² ΡΠ»ΡΡΠ°Π΅ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΠ ΠΈ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡΠΊ ΡΠ°Π½Π½Π΅ΠΌΡ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² ΠΠ ΠΈ Π±ΡΡΡΡΠΎΠΉ ΠΈΡ
Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅, ΠΌΠ΅Π½ΡΡΠ°Ρ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΡΠ²Π΅ΡΠ»ΡΡ
ΠΏΡΠΎΠΌΠ΅ΠΆΡΡΠΊΠΎΠ² ΠΠ ΠΈ ΠΠ, ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π½ΠΈΠ·ΠΊΠ°Ρ ΡΠΎΠ»Π΅ΡΠ°Π½ΡΠ½ΠΎΡΡΡ ΠΊ ΡΠΏΠΈΡΡΠ½ΠΎΠΌΡ, Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½ Π΄Π΅ΠΏΡΠ΅ΡΡΠΎΠ³Π΅Π½Π½ΡΠΉ ΡΡΡΠ΅ΠΊΡ ΡΡΠΈΠ»ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΏΠΈΡΡΠ°
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π°Π½ΡΠΈΠ΄Π΅ΠΏΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ² ΠΏΡΠΈ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΠΈ Ρ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡΡ
Β Aim. To determine the nosological and clinical features of mood disorders (MD) with comorbid alcohol use disorder (AUD) and efficiency of antidepressant therapy.Materials and methods. We examined 88 patients with MD and comorbid AUD β 33 females (37.5%) and 55 males (62.5%). The first group included 31 patients with AUD without comorbid affective symptoms, the second group contained 29 patients with MD without AUD, the third group included 28 patients with AUD and MD. In the study, we applied clinical-psychopathologic, clinical-dynamic, and statistical methods with Pearsonβs Ο2 test, Mann β Whitney U-test (for comparison of independent samples), Kruskal β Wallis test (for more than two independent samples), and Wilcoxon test (for comparison of dependent samples). At the level of statisticalΒ significance, no differences between the groups according to the gender β age composition were revealed (p = 0.115 β according to gender composition, Ρ = 0.248 β according to age composition, Pearsonβs Ο2 test).Results. The patients with the diagnosis of AUD with comorbid MD showed worse dynamics of the reduction of depressive [from 24.0 (18.3; 33.0) to 9.0 (4.3; 12.0) points according to the Structured Interview Guide for the Hamilton Depression Rating Scale β Seasonal Affective Disorder (SIGH-SAD)Β (Ρ = 0.001, Wilcoxon test)] and anxiety [from 20.5 (12.5; 25.0) to 5.5 (3.3; 8.0) points according to the Hamilton Anxiety Rating Scale (HARS) (Ρ = 0.001, Wilcoxon test)] symptoms against the background of the therapy with initially lower indices compared to the group with MD alone [from 27.0 (21.0; 36.0) to 6.0 (5.0; 11.0) points according to SIGH-SAD (Ρ = 0.001, Wilcoxon test) (intergroup differences upon admission Ρ = 0.046; uponΒ discharge Ρ = 0.683, Mann β Whitney U-test) and from 21.0 (14.0; 29.0) to 5.0 (3; 10.5) points according to HARS (Ρ = 0.001, Wilcoxon test) (intergroup differences upon admission Ρ = 0.082; upon discharge Ρ = 0.825, Mann βΒ Whitney U-test)]. The course of AUD is characterized by a larger extent of malignancy in the group with a comorbidity: decrease in pathologicalΒ alcohol craving from 31.5 (16.3; 43.5) points to 8 (2.3; 14.8) (Ρ = 0.001, Wilcoxon test) in the group with a comorbidity and from 29.5 (21.8; 37.0) to 7 (3.0; 11.3) points with AUD alone (Ρ = 0.001, Wilcoxon test) (intergroupΒ differences upon admission Ρ = 0.058; upon discharge Ρ = 0.04, Mann β Whitney U-test on the Obsessive Compulsive Drinking Scale (OCDS).Conclusion. Clinical-dynamic characteristics of MD with comorbid AUDΒ result in therapeutic difficulties associated with comparatively worse dynamics of reduction of the symptoms of both diseases. Β Β Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΡΠΊΡΡΡΡ, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ² (ΠΠ ) ΠΏΡΠΈ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΠΈ Ρ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉΒ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡΡ (ΠΠ) ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π°Π½ΡΠΈΠ΄Π΅ΠΏΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠΉΒ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 88 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ Ρ ΠΠ ΠΈ ΠΠ β 33 ΠΆΠ΅Π½ΡΠΈΠ½Ρ (37,5%) ΠΈ 55 (62,5%) ΠΌΡΠΆΡΠΈΠ½. ΠΠ΅ΡΠ²Π°Ρ Π³ΡΡΠΏΠΏΠ° β 31 ΠΏΠ°ΡΠΈΠ΅Π½Ρ Ρ ΠΠ Π±Π΅Π· ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΠΉ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉΒ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΠΊΠΈ, Π²ΡΠΎΡΠ°Ρ β 29 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²ΠΎΠΌ Π½Π°ΡΡΡΠΎΠ΅Π½ΠΈΡ Π±Π΅Π· Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π°Π»ΠΊΠΎΠ³ΠΎΠ»Ρ, ΡΡΠ΅ΡΡΡ β 28Β ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΠ ΠΈ ΠΠ . Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈΡΡ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΏΡΠΈΡ
ΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ,Β ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄Ρ ΡΒ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² Ο2 ΠΠΈΡΡΠΎΠ½Π°, ΠΠ°Π½Π½Π° β Π£ΠΈΡΠ½ΠΈ (Π΄Π»ΡΒ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΡ
Π²ΡΠ±ΠΎΡΠΎΠΊ), ΠΡΠ°ΡΠΊΠ΅Π»Π° β Π£ΠΎΠ»Π»ΠΈΡΠ° (Π΄Π»Ρ Π±ΠΎΠ»Π΅Π΅ Π΄Π²ΡΡ
Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΡ
Π²ΡΠ±ΠΎΡΠΎΠΊ), ΠΠΈΠ»ΠΊΠΎΠΊΡΠΎΠ½Π° (Π΄Π»ΡΒ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Π·Π°Π²ΠΈΡΠΈΠΌΡΡ
Π²ΡΠ±ΠΎΡΠΎΠΊ). ΠΠΎ ΡΡΠΎΠ²Π½Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ ΠΏΠΎ ΠΏΠΎΠ»ΠΎΠ²ΠΎΠ·ΡΠ°ΡΡΠ½ΠΎΠΌΡ ΡΠΎΡΡΠ°Π²Ρ Π½Π΅ Π²ΡΡΠ²Π»Π΅Π½ΠΎ (p = 0,115 β ΠΏΠΎ ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΌΡ ΡΠΎΡΡΠ°Π²Ρ, Ρ = 0,248 β ΠΏΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΠΎΠΌΡ ΡΠΎΡΡΠ°Π²Ρ, ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ Ο2).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ°ΡΠΈΠ΅Π½ΡΡ Ρ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΡΠΌ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ ΠΠ ΠΈ ΠΠ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΡΡ Ρ
ΡΠ΄ΡΡΡ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡ ΡΠ΅Π΄ΡΠΊΡΠΈΠΈ Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠΉ (Ρ 24,0 (18,3; 33,0) Π΄ΠΎ 9,0 (4,3; 12,0) Π±Π°Π»Π»ΠΎΠ² ΠΏΠΎ ΡΠΊΠ°Π»Π΅ SIGH-SAD (Ρ = 0,001, ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠΈΠ»ΠΊΠΎΠΊΡΠΎΠ½Π°)) ΠΈ ΡΡΠ΅Π²ΠΎΠΆΠ½ΠΎΠΉ (Ρ 20,5 (12,5; 25,0) Π΄ΠΎ 5,5 (3,3; 8,0) Π±Π°Π»Π»ΠΎΠ² ΠΏΠΎ ΡΠΊΠ°Π»Π΅ HARS (Ρ = 0,001, ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠΈΠ»ΠΊΠΎΠΊΡΠΎΠ½Π°)) ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΠΊΠΈ Π½Π° ΡΠΎΠ½Π΅ Π»Π΅ΡΠ΅Π½ΠΈΡ, ΠΏΡΠΈ ΠΈΠ·Π½Π°ΡΠ°Π»ΡΠ½ΠΎ Π±ΠΎΠ»Π΅Π΅ Π½ΠΈΠ·ΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΡ
, Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ Π³ΡΡΠΏΠΏΠΎΠΉ Ρ Β«ΡΠΈΡΡΡΠΌΠΈΒ» ΠΠ (Ρ 27,0 (21,0; 36,0) Π΄ΠΎ 6,0 (5,0; 11,0) Π±Π°Π»Π»ΠΎΠ² ΠΏΠΎ SIGH-SAD (Ρ = 0,001, ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠΈΠ»ΠΊΠΎΠΊΡΠΎΠ½Π°) (ΠΌΠ΅ΠΆΠ³ΡΡΠΏΠΏΠΎΠ²ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΏΡΠΈ ΠΏΠΎΡΡΡΠΏΠ»Π΅Π½ΠΈΠΈ Ρ = 0,046; ΠΏΡΠΈΒ Π²ΡΠΏΠΈΡΠΊΠ΅ Ρ = 0,683, ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠ°Π½Π½Π° β Π£ΠΈΡΠ½ΠΈ) ΠΈ Ρ 21,0 (14,0; 29,0) Π΄ΠΎ 5,0 (3; 10,5) Π±Π°Π»Π»ΠΎΠ² ΠΏΠΎ HARS (Ρ = 0,001, ΠΊΡΠΈΡΠ΅ΡΠΈΠΉΒ ΠΠΈΠ»ΠΊΠΎΠΊΡΠΎΠ½Π°) (ΠΌΠ΅ΠΆΠ³ΡΡΠΏΠΏΠΎΠ²ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΏΡΠΈ ΠΏΠΎΡΡΡΠΏΠ»Π΅Π½ΠΈΠΈ Ρ =Β 0,082; ΠΏΡΠΈ Π²ΡΠΏΠΈΡΠΊΠ΅ Ρ = 0,825, ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠ°Π½Π½Π° β Π£ΠΈΡΠ½ΠΈ)).Β Π’Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΠ ΠΎΡΠ»ΠΈΡΠ°Π΅ΡΡΡ Π±ΠΎΠ»ΡΡΠ΅ΠΉ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΡΡΡΡ Π² Π³ΡΡΠΏΠΏΠ΅ Ρ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΡΡ: ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΊ Π°Π»ΠΊΠΎΠ³ΠΎΠ»Ρ Ρ 31,5 (16,3; 43,5) Π±Π°Π»Π»Π° Π΄ΠΎ 8 (2,3; 14,8) (Ρ = 0,001, ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠΈΠ»ΠΊΠΎΠΊΡΠΎΠ½Π°) Π² Π³ΡΡΠΏΠΏΠ΅ Ρ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΡΡ ΠΈ Ρ 29,5 (21,8; 37,0) Π΄ΠΎ 7 (3,0; 11,3) Π±Π°Π»Π»ΠΎΠ²Β ΠΏΡΠΈ Β«ΡΠΈΡΡΠΎΠΉΒ» ΠΠ (Ρ = 0,001, ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠΈΠ»ΠΊΠΎΠΊΡΠΎΠ½Π°) (ΠΌΠ΅ΠΆΠ³ΡΡΠΏΠΏΠΎΠ²ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΏΡΠΈ ΠΏΠΎΡΡΡΠΏΠ»Π΅Π½ΠΈΠΈ Ρ = 0,058; ΠΏΡΠΈΒ Π²ΡΠΏΠΈΡΠΊΠ΅ Ρ = 0,04, ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠ°Π½Π½Π° β Π£ΠΈΡΠ½ΠΈ ΠΏΠΎ ΠΎΠ±ΡΠ΅ΡΡΠΈΠ²Π½ΠΎ-ΠΊΠΎΠΌΠΏΡΠ»ΡΡΠΈΠ²Π½ΠΎΠΉ ΡΠΊΠ°Π»Π΅ ΡΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΡ Π°Π»ΠΊΠΎΠ³ΠΎΠ»Ρ).Β ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈΒ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΡ ΠΠ ΠΈ ΠΠ Π²Π΅Π΄ΡΡ ΠΊ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΒ Π·Π°ΡΡΡΠ΄Π½Π΅Π½ΠΈΡΠΌ, ΡΠΎΠΏΡΡΠΆΠ΅Π½Π½ΡΠΌ ΡΠΎ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎ Ρ
ΡΠ΄ΡΠ΅ΠΉΒ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΎΠΉ ΡΠ΅Π΄ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² ΠΊΠ°ΠΆΠ΄ΠΎΠ³ΠΎ ΠΈΠ· Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ.
ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠ΅ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π° ΠΏΡΠΈ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΠΈ Ρ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡΡ: ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ, ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°Π΄Π°ΠΏΡΠ°ΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
The aim of the study was to reveal clinical and dynamic characteristics of affective disorders (AD) inΒ comorbidity with alcohol addiction (AA).Materials and methods. 65 patients with affective disorders [22 women (34%) and 43 men (66%)] wereΒ examined. The main group included 34 patients aged 44.5 [36.0; 51.5] with affective disorders and comorbidΒ alcohol addiction The comparison group included 31 patients aged 45 years [32; 52] with affective disordersΒ without comorbid narcological pathology. Compared groups were matched by sex, age and nosologicalΒ structure (p > 0.05). The following methods were used in the study: clinical and psychopathological, clinicalΒ follow-up, psychometric, statistical, as well as these psychometric scales: Clinical Global Impression (CGI),Β Hamilton Depression Rating Scale (HDRS-17), Hamilton Anxiety Rating Scale (HARS), Social AdaptationΒ Self-evaluation Scale (SASS).Results. The comparative assessment of clinical and dynamic characteristics of affective disorders andΒ social adaptation level was conducted. Chronology of occurrence of comorbid affective disorders andΒ alcohol addiction was analyzed.Conclusion. Addition of alcohol addiction to affective disorders worsens the clinical and dynamic indicesΒ and social adaptation level of patients.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β Π²ΡΡΠ²Π»Π΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Β (ΠΠ ) ΠΏΡΠΈ ΠΈΡ
ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΠΈ Ρ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡΡ (ΠΠ).ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ 65 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ β 22 ΠΆΠ΅Π½ΡΠΈΠ½Ρ (34%) ΠΈ 43 (66%) ΠΌΡΠΆΡΠΈΠ½Ρ.Β ΠΡΠ½ΠΎΠ²Π½Π°Ρ Π³ΡΡΠΏΠΏΠ° β 34 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌΠΈ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π°ΠΌΠΈ ΠΈ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΠΉ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉΒ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡΡ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ 44,5 Π»Π΅Ρ [36,0; 51,5]. ΠΡΡΠΏΠΏΠ° ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ β 31 ΠΏΠ°ΡΠΈΠ΅Π½Ρ Ρ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌΠΈΒ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π°ΠΌΠΈ Π±Π΅Π· ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΠΉ Π½Π°ΡΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ 45 Π»Π΅Ρ [32; 52].Β Π‘ΡΠ°Π²Π½ΠΈΠ²Π°Π΅ΠΌΡΠ΅ Π³ΡΡΠΏΠΏΡ Π±ΡΠ»ΠΈ ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΡ ΠΏΠΎ ΠΏΠΎΠ»Ρ, Π²ΠΎΠ·ΡΠ°ΡΡΡ ΠΈ Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΡΠΊΡΡΡΠ΅ (p > 0,05).Β Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈΡΡ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΏΡΠΈΡ
ΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ, ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΊΠ°ΡΠ°ΠΌΠ½Π΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ, ΠΏΡΠΈΡ
ΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ, ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΈΡ
ΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠΊΠ°Π»Ρ: ΡΠΊΠ°Π»Π° Π³Π»ΠΎΠ±Π°Π»ΡΠ½ΠΎΠΉΒ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠΈ CGI, ΡΠΊΠ°Π»Π° Π΄Π΅ΠΏΡΠ΅ΡΡΠΈΠΈ ΠΠ°ΠΌΠΈΠ»ΡΡΠΎΠ½Π° HDRS-17, ΡΠΊΠ°Π»Π° ΡΡΠ΅Π²ΠΎΠ³ΠΈ ΠΠ°ΠΌΠΈΠ»ΡΡΠΎΠ½Π° HARS,Β ΡΠΊΠ°Π»Π° ΡΠ°ΠΌΠΎΠΎΡΠ΅Π½ΠΊΠΈ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°Π΄Π°ΠΏΡΠ°ΡΠΈΠΈ SASS.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
Β ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ² ΠΈ ΡΡΠΎΠ²Π½Ρ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°Π΄Π°ΠΏΡΠ°ΡΠΈΠΈ. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π° Ρ
ΡΠΎΠ½ΠΎΠ»ΠΎΠ³ΠΈΡ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡΒ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΡΡ
Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ² ΠΈ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΈΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠ΅ Π°Π»ΠΊΠΎΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΊ Π°ΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π°ΠΌ ΡΡ
ΡΠ΄ΡΠ°Π΅Ρ ΠΈΡ
Β ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΈ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°Π΄Π°ΠΏΡΠ°ΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
Association of COMT gene polymorphisms with Parkinson's disease
Parkinsonβs disease (PD) is one of the most serious and widespread neurodegenerative disorders. Genetic susceptibility plays a significant role in the development of PD.The aim of our study was to investigate associations between single nucleotide polymorphisms (SNPs) of the COMT gene coding dopamine catabolism enzyme and Parkinsonβs disease.Materials and methods. In this study seven SNPs (rs4680, rs6269, rs4633, rs4818, rs769224, rs165774, rs174696) of COMT were genotyped. 232 patients with PD and 127 healthy individuals in the Siberian region of Russia were examined. Venous blood samples were drawn as a marker of PD. Statistical differences in the prevalence of alleles and genotypes between groups of patients were assessed using IBM SPSS Statistics 23.1 software.Results. A significant association between the rs165774 polymorphism and PD was observed. Our study demonstrates that polymorphisms in the COMT gene may play an important role in the pathophysiology of Parkinsonβs disease
- β¦